LGALS3 and pulmonary arterial hypertension: The association between risk profiles and plasma levels of Gal-3 cannot be considered a demonstration that Gal-3 is a clinically useful prognostic marker; however, given that such multidimensional risk profiles have been tested and validated for prognostic stratification of PAH patients, the association is a valid and strong proof of concept for a prospective study aimed at evaluating whether Gal-3 may provide additional prognostic information in PAH patients.